Federal Circuit Affirms Patent-Ineligibility of Claims Directed to Displaying Financial Information on a Known Device
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
Before Moore, Clevenger, and Wallach. Appeal from the Patent Trial and Appeal Board.
Summary: Claims directed to providing additional trading information on a prior art display, without more, are patent-ineligible under 35 U.S.C. § 101.
IBG and Interactive Brokers petitioned for Covered Business Method (CBM) review of a Trading Technologies (TT) patent directed to providing new or different trading information to traders via a trading screen. The Board held the patent met the statutory definition of a “covered business method” patent and held all claims were patent-ineligible under 35 U.S.C. § 101. TT appealed both issues.
The Federal Circuit agreed that the patent met the definition of a CBM patent because the claims failed to provide a technical solution to a technical problem. In particular, the Federal Circuit held that providing new or different information to traders on a prior art trading screen “focuses on improving the trader, not the functioning of the computer.”
The Federal Circuit also affirmed the claims were patent-ineligible under § 101. Regarding step one of the Alice analysis, the claims were directed to an abstract idea because their “purported advance” was gathering, analyzing, and displaying market information without solving a technological problem. Regarding step two, the claims failed to amount to “significantly more” than an abstract idea because they merely added conventional information to a prior art trading screen.
More insights
Fresh From the Bench: Latest Precedential Patent Case
Ridge Corp. et al. v. Kirk NationaLease Co. et al. , Appeal No. 2025-1254 (Fed. Cir. July 13, 2026) In its only precedential patent opinion last week, the Federal Circuit considered an appeal of a preliminary injunction issued by the U.S. District Court…
Fresh From the Bench: Latest Precedential Patent Cases
CASE OF THE WEEK Wyeth LLC v. AstraZeneca Pharmaceuticals LP , Appeal No. 2024-2325 (Fed. Cir. July 9, 2026) In our Case of the Week, the Federal Circuit affirmed a district court ruling reversing a $107.5 million jury verdict against AstraZeneca in a case…
Enanta Pharmaceuticals, Inc. v. Pfizer Inc., Appeal No. 2025-1427 (Fed. Cir. Jun. 23, 2026)
CASE OF THE WEEK Enanta Pharmaceuticals, Inc. v. Pfizer Inc., Appeal No. 2025-1427 (Fed. Cir. Jun. 23, 2026) In our Case of the Week, the Federal Circuit affirmed summary judgment invalidating all claims of Enanta’s Patent No. 11,358,953 as…